Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
暂无分享，去创建一个
F. Penault-Llorca | N. Radosevic-Robin | T. Petit | O. Trédan | M. Mouret-Reynier | P. Dubray-Longeras | I. van Praagh | C. Abrial | F. Kwiatkowski | L. Vanlemmens | S. Kullab | K. Benmammar | J. Gligorov | P. Chollet | N. Chalabi | J. Nabholtz | N. Uhrhammer | A. Desrichard | A. Cayre | M. Dauplat | C. Jouannaud | N. Tubiana-Mathieu | S. Guiu | B. Weber | F. Penault-Llorca | M. Bahadoor | I. V. Praagh | A. Forest | Bettina Weber | J. Nabholtz